Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LENZ LENZ Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: LENZ
Price (delayed)
$26.34
Market cap
$741.37M
P/E Ratio
59.86
Dividend/share
N/A
EPS
$0.44
Enterprise value
$718.89M
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process
Highlights
The EPS has soared by 119% from the previous quarter and by 101% YoY
LENZ Therapeutics's quick ratio has soared by 100% YoY and by 13% from the previous quarter
The equity has declined by 6% since the previous quarter and by 3.1% year-on-year
Key stats
What are the main financial stats of LENZ
Market
Valuations
Earnings
Shares outstanding
28.15M
Market cap
$741.37M
Enterprise value
$718.89M
Price to earnings (P/E)
59.86
Price to book (P/B)
3.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$59.45M
Net income
-$47.74M
EBIT
-$47.74M
EBITDA
-$47.65M
Free cash flow
-$52.08M
Per share
Balance sheet
Liquidity
EPS
$0.44
EPS diluted
$0.44
Free cash flow per share
-$1.89
Book value per share
$6.97
Revenue per share
$0
TBVPS
$7.31
Total assets
$201.25M
Total liabilities
$9.24M
Debt
$673,000
Equity
$192.01M
Working capital
$189.29M
Debt to equity
0
Current ratio
23.09
Quick ratio
22.65
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22.6%
Return on equity
-23.7%
Return on invested capital
-29.7%
Return on capital employed
-24.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LENZ stock price
How has the LENZ Therapeutics stock price performed over time
Intraday
1.82%
1 week
-10.77%
1 month
28.99%
1 year
71.04%
YTD
-8.76%
QTD
2.45%
Financial performance
How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.45M
Net income
-$47.74M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 35% YoY and by 4.1% QoQ
LENZ's operating income is up by 22% year-on-year
Price vs fundamentals
How does LENZ's price correlate with its fundamentals
Growth
What is LENZ Therapeutics's growth rate over time
Valuation
What is LENZ Therapeutics stock price valuation
P/E
59.86
P/B
3.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 119% from the previous quarter and by 101% YoY
The stock's price to book (P/B) is 18% more than its last 4 quarters average of 3.2
The equity has declined by 6% since the previous quarter and by 3.1% year-on-year
Efficiency
How efficient is LENZ Therapeutics business performance
The return on invested capital has surged by 66% year-on-year and by 30% since the previous quarter
LENZ Therapeutics's ROE has soared by 57% YoY and by 3.7% from the previous quarter
LENZ's return on assets is up by 36% year-on-year and by 2.6% since the previous quarter
Dividends
What is LENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LENZ.
Financial health
How did LENZ Therapeutics financials performed over time
LENZ Therapeutics's current ratio has soared by 101% YoY and by 13% from the previous quarter
LENZ Therapeutics's quick ratio has soared by 100% YoY and by 13% from the previous quarter
LENZ Therapeutics's debt is 100% lower than its equity
LENZ Therapeutics's debt has decreased by 17% QoQ
The equity has declined by 6% since the previous quarter and by 3.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.